Project UpdateJul 16, 2026, 07:46 AM
Galmed develops novel cardiac-targeted Aramchol LNP formulation
AI Summary
Galmed Pharmaceuticals announced a breakthrough in developing a novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, in collaboration with Barcode Nanotech. This new formulation is designed to specifically target heart tissue, redirecting Aramchol's biodistribution away from the liver. The goal is to create a disease-modifying therapy for cardiac fibrosis, a major cause of chronic heart failure, leveraging Aramchol's known anti-fibrotic effects.
Key Highlights
- Galmed developed a novel LNP formulation of Aramchol with Barcode Nanotech.
- The new formulation targets heart tissue, redirecting Aramchol from the liver.
- Traditional Aramchol formulation accumulates 80-90% in the liver, with limited heart effect.
- Aramchol showed anti-fibrotic effects in liver (MASH study), human heart organoids, and in-vivo models.
- Cardiac fibrosis is a major driver of chronic heart failure, responsible for 20.5 million deaths in 2025.
- The LNP Aramchol formulation could become a disease-modifying therapy for cardiac fibrosis.
- Collaboration uses advanced formulation science, in vivo screening, and AI-enabled analysis.
Price Impact
More from GLMD